<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464607</url>
  </required_header>
  <id_info>
    <org_study_id>00IF/HMG06</org_study_id>
    <nct_id>NCT00464607</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized, Controlled, Clinical Study on Tolerability and Efficacy of hMG-IBSA</brief_title>
  <official_title>A Prospective, Randomized, Controlled Clinical Study on the Assessment of Tolerability and of Clinical Efficacy of MERIONAL® (hMG-IBSA) Administered Subcutaneously Versus MERIONALâ Administered Intramuscularly in Women Undergoing Controlled Ovarian Hyperstimulation (COH) in an ART Programme (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is the evaluation of the tolerability (both local and systemic) and the&#xD;
      clinical efficacy (in terms oocytes recovered) of subcutaneously versus intramuscularly&#xD;
      administered Merional® (IBSA, Lugano - CH) in patients undergoing controlled ovarian&#xD;
      hyperstimulation (COH) in an ART programme (IVF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes recovered</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Day of Oocyte collection, 17β-estradiol Cmax, Total dose of gonadotrophin (IU) or n° of vials and n° of vials/day,Number of mature follicles (follicles ³ 16 mm in diameter) on hCG day (or one day earlier), Clinical pregnancy rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability: Number of Adverse Events (AEs) experienced during the study, Occurrence of Ovarian Hypestimulation Syndrome (OHSS), Local tolerability at the injection site, Haematological-biochemical laboratory tests, before and after treatment,</measure>
  </secondary_outcome>
  <enrollment>160</enrollment>
  <condition>Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMG-IBSA</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ovarian stimulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients&#xD;
&#xD;
          -  aged between 20 and 40 years&#xD;
&#xD;
          -  undergoing ovarian stimulation for the purposes of oocyte retrieval in an assisted&#xD;
             conception programme&#xD;
&#xD;
          -  Body Mass Index (BMI) 20-28 kg/m2&#xD;
&#xD;
          -  early follicular phase FSH level &lt; 9 IU/l.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ascertained or presumptive hypersensitivity to the active principle and/or their&#xD;
             ingredients&#xD;
&#xD;
          -  primary ovarian failure&#xD;
&#xD;
          -  ovarian cysts or enlargement not due to polycystic ovarian syndrome&#xD;
&#xD;
          -  oocyte donation&#xD;
&#xD;
          -  abnormal bleeding of undetermined origin&#xD;
&#xD;
          -  patients who have exhibited poor response or requiring doses of more than 300 IU daily&#xD;
             in previous treatment cycles or those who have received similar therapies (previous&#xD;
             treatment cycles) in the 30 days prior to the beginning of the present study&#xD;
&#xD;
          -  uncontrolled thyroid or adrenal dysfunction&#xD;
&#xD;
          -  neoplasia&#xD;
&#xD;
          -  severe impairment of the renal and/or hepatic functions&#xD;
&#xD;
          -  diabetes and active thrombophlebitis, cardiopathies and epilepsy&#xD;
&#xD;
          -  presence of clinically significant systemic disease or any contraindication of being&#xD;
             pregnant and/or carrying out a pregnancy to term&#xD;
&#xD;
          -  presence of any anatomical abnormality of the reproductive system&#xD;
&#xD;
          -  being pregnant or breastfeeding&#xD;
&#xD;
          -  menopause&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Ragni, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale S.Martino - Genova (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Fedele, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale S. Paolo - Milano (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe De Placido, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Federico II - Napoli (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Massobrio, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale S. Anna - Torino (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale S. Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Paolo</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Anna</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 20, 2007</study_first_submitted>
  <study_first_submitted_qc>April 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2007</study_first_posted>
  <last_update_submitted>April 20, 2007</last_update_submitted>
  <last_update_submitted_qc>April 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

